QuidelOrtho reports Q1 adjusted EPS $1.80, consensus $1.49

Reports Q1 revenue $846.1M, consensus $794.05M. "We’re off to an excellent start to the year with strong results across all geographic regions, double-digit growth in our Labs business, and better-than-expected Point of Care sales, demonstrating the power of our newly created scale and breadth of offerings across the diagnostics continuum," said Douglas Bryant, President and Chief Executive Officer of QuidelOrtho. "The strength of our Labs business was particularly notable, with solid demand for both consumables and instruments, including standalone and integrated, as well as automation, setting us up for a stronger second half of the year."